The malignant lymphomas comprise a heterogeneous group of neoplastic diseases of the lymphatic system. In the WHO classification 70 different entities are subdivided. Each type of lymphoma is defined as a disease with specific clinical characteristics, as well as morphological, immunophenotypic and genetic characteristics. The indolent lymphomas include follicular lymphoma, marginal zone lymphoma, Lymphoplasmacytic lymphoma, small cell lymphocytic lymhoma/chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia. Indolent lymphomas are characterized by slow growth and a chronic course of the disease. Antibody-based therapies, have significantly improved the prognosis, nevertheless there is no curative treatment. Watch and wait is still an reasonable option in asymptomatic patients. The goal of therapy has been to maintain the best quality of life. and to avoid late toxicities. The following review presents the current treatment options.